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ABSTRACT
OBJECTIVE: The objective of this selective EBM review is to determine whether or not
treatment with onabotulinumtoxinA improves the quality of life in patients with urinary
incontinence not adequately controlled with anticholinergics.
STUDY DESIGN: Review of three English language, randomized controlled trials published in
2013.
DATA SOURCES: Randomized, double-blind, controlled clinical trials comparing
onabotulinumtoxinA intradetrusor injections with saline placebo. All articles were found using
PubMed.
OUTCOMES MEASURED: Each of the three trials assessed the patient’s quality of life after
treatment with onabotulinumtoxinA using the following assessment tools: Incontinence Quality
of Life Questionnaire (I-QOL), Modified Overactive Bladder Patient Satisfaction with Treatment
Questionnaire (OAB-PSTQ), King’s Health Questionnaire (KHQ), Patient Global Assessment
(PGA), and Treatment Benefit Scale.
RESULTS: Both the Chancellor et al. and the Sussman et al. studies found a statistically
significant improvement in the change from baseline in the I-QOL and OAB-PSTQ for the
patients who received onabotulinumtoxinA compared to placebo (p value < 0.001). Nitti et al.
demonstrated an improvement range of 19.6 to 23.9 ± SD change from baseline in the I-QOL
score for the onabotulinumtoxinA treatment group. 60.8% of the experimental group in Nitti et
al. reported a positive treatment response after onabotulinumtoxinA while only 29.2% of placebo
patients reported this response (p value < 0.001). Sussman et al established an inverse
correlation between I-QOL total scores and UI frequency with a Pearson’s correlation coefficient
of -0.508 at week 12 establishing that decreased frequency in urinary incontinence events are
associated with improved quality of life.
CONCLUSIONS: Based on the three trials, onabotulinumtoxinA does improve quality of life in
patients with urinary incontinence not adequately controlled with anticholinergics by improving
patient satisfaction with treatment, urinary incontinence symptoms, and healthcare related quality
of life.
KEY WORDS: Urinary incontinence, Overactive bladder, OnabotulinumtoxinA
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INTRODUCTION
Urinary incontinence (UI) is a condition in which there is an involuntary loss of urine and
includes the classifications of stress, urge, overflow, and mixed incontinence. Urge
incontinence, which is also known as overactive bladder (OAB), is detrusor overactivity that
results in uninhibited bladder contractions and subsequent leakage of urine.1 This paper
evaluates three randomized, double blind, controlled trials comparing the efficacy of
onabotulinumtoxinA for improving overall health related quality of life (HRQOL) in patients
who have uncontrolled urge incontinence.
Overactive bladder is a disorder that is quite common in the medical field. The incidence
of urge urinary incontinence in the US is 2.6-14.2% in men and 8.9-36.3% in women with
increasing incidence in females, increased age, increased BMI, and limited physical activity.1,2
Incidence is expected to increase from 11.6% in 2013 to 23.6% in 2018.2 The estimated total
national cost for urge urinary incontinence is $65.9 billion annually and is expected to increase
due to the aging population.2 Overall, the mean annual cost of care for individual incontinence
management is $751.3 The exact number of healthcare visits is unknown due to the fact that
many patients do not report symptoms of urge urinary incontinence to their medical providers
due to reasons such as embarrassment and lack of knowledge.
Symptoms of OAB include an intense urge to urinate, leakage of urine, and nocturia. The
etiology of urge incontinence is typically idiopathic but it can be also be contributed to bladder
stones, bladder tumors, urinary tract infections, central nervous system lesions, or nerve injury.1
These symptoms can have a profound impact on a patient’s life causing patients to avoid social
situations, feel embarrassment, and prevent them from performing various activities.
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There are various methods that are utilized in order to treat urge incontinence. Lifestyle
modifications such as weight loss and caffeine reduction are helpful in patients whose symptoms
are minor. Kegel exercises with or without biofeedback can be done frequently to strengthen
pelvic floor muscles, thus providing support and strength for the detrusor muscles.1 Bladder
training or prompted voiding are other methods to alleviate symptoms. The mainstay of drug
therapy is antimuscarinic oral therapy, which is available in either short acting or long acting
formulations. Examples of such anticholinergic treatment are Tolterodine or Oxybutynin taken
2-3 times per day1. Other treatment includes onabotulinumtoxinA injections in the detrusor
muscle, which is considered alternative treatment for refractory cases. Adjunctive therapy such
as alpha blockers and topical estrogens can also be utilized for effective treatment.1 If all of the
aforementioned treatment fails, surgery and nerve stimulation can be performed.
There are various severities associated with urge urinary incontinence and the treatment
options mentioned above have all been proven to be effective treatments. Besides
anticholinergic medications, there are limited pharmacological options for urinary incontinence.
Intradetrusor injections of onabotulinumtoxinA has been utilized as an effective treatment for
patients who have not had success with anticholinergic treatment. Its effects and efficacy have
been thoroughly studied and continue to be monitored, leading to the rise of its utilization in
treatment for OAB patients.
OBJECTIVE
The objective of this selective EBM review is to determine whether or not treatment with
onabotulinumtoxinA improves the quality of life in patients with urinary incontinence not
adequately controlled with anticholinergics.
METHODS
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An established criteria was utilized for the selection of each study. The chosen
population was males and females 18-80 years old diagnosed with overactive bladder whose
symptoms were not adequately managed with anticholinergic drug therapy. The common
intervention among all studies was intradetrusor injections of onabotulinumtoxinA in dosages of
either 100, 200, or 300 units. Patients received either 1 mL of onabotulinumtoxinA for 30
intradetrusor injections or 0.5 mL for 20 intradetrusor injections. Comparisons were made
between the treatment group who received onabotulinumtoxinA and the experimental group of
patients who received a placebo of normal saline administered via cystoscopy or intradetrusor
injection. The outcomes that were measured were the impact of onabotulinumtoxinA on the
patient’s health related quality of life (HRQOL) and overall patient satisfaction with treatment.
All 3 studies were randomized, double blind, placebo controlled clinical trials (RCT).
Each article was published in a peer-reviewed journal and in the English language. Key words
that were utilized in searching include “urinary incontinence”, “overactive bladder”, and
“onabotulinumtoxinA”. Data sources for the systematic review were selected from PubMed by
the author throughout December of 2013. Articles were selected based on their relevance to the
author’s clinical question and if they included patient oriented outcomes (POEM). Inclusion
criteria included RCTs that were published after 2007 and patients greater than 18 years old with
overactive bladder. Exclusion criteria included patients less than 18 years old and patients
whose overactive bladder symptoms were controlled by anticholinergic therapy. A summary of
the statistics reported or used in the 3 RCTs include control event rate (CER), experimental event
rate (EER), relative benefit increase (RBI), absolute benefit increase (ABI), numbers needed to
treat (NNT), Pearson’s coefficient, confidence interval (CI), and p-values.
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Table 1: Demographics & Characteristics of Included Studies
Study

Type
RCT

#
Pts
416

Age
(yrs)
18-80

Chancellor4
(2013)

Nitti5
(2013)

RCT

557

≥ 18

Sussman6
(2013)

RCT

275

18-80

Inclusion Criteria

Exclusion
W/D
Criteria
-Age 18-80 years
-Patients with
17
old with multiple
pelvic or urologic
sclerosis or spinal abnormalities
cord injury who
-Previous
had ≥ 14 urinary
botulinum toxin
incontinence
therapy for
episodes/wk due to urologic
neurogenic
conditions
detrusor
-Symptoms
overactivity
adequately
-Symptoms not
controlled by
adequately
anticholinergics
controlled by
anticholinergics
- ≥ 18 years old
-Patients with a
65
with idiopathic
predominance of
overactive bladder stress incontinence
- ≥ 3 urgency
-Post void residual
urinary
urine volume ≤
incontinence
100 mL
episodes in a 3 day -Patients unwilling
period
to perform clean
-Average ≥ 8
intermittent
micturitions/day
catheterization if
-Symptoms not
required
adequately
controlled by
anticholinergics
-Age 18-80 years
-History of or
0
old with multiple
current bladder
sclerosis or spinal conditions
cord injury who
-Any surgeries that
had ≥ 14 urinary
could affect
incontinence
bladder function
episodes/wk due to -Previous
neurogenic
botulinum toxin
detrusor
therapy for
overactivity
urologic
-Symptoms not
conditions
adequately
-24-hour total
controlled by
voided volume >
anticholinergics
3,000 mL
-Post-void residual
> 200mL

Intervention
30 intradetrusor
injections (1
mL each) of
onabotulinumtoxinA 200 or
300 U

20 intradetrusor
injections (0.5
mL each) of
onabotulinum
toxinA 100 U

30 intradetrusor
injections (1
mL each) of
onabotulinum
toxinA 200 or
300 U
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OUTCOMES MEASURED
All outcomes that were measured were those of patient-oriented evidence (POEM) and
were collected via patient-reported questionnaires. For all 3 randomized clinical trials,
questionnaires were filled out by patients repeatedly throughout the study at various posttreatment visits. Statistical analysis was performed on the intent-to-treat population.
In both the Chancellor et al study and the Sussman et al study, the Incontinence Quality
of Life Questionnaire (I-QOL), the Modified Overactive Bladder Patient Satisfaction with
Treatment Questionnaire (OAB-PSTQ), and the Patient Global Assessment (PGA) were
utilized.4,6 I-QOL is a 22 item questionnaire that assesses the impact of UI on a patient’s life.
Scores range from 0-100 with higher scores reflecting better quality of life.4,6 Included in this
questionnaire are the three other domain scores of avoidance and limiting behavior, psychosocial
impact, and social embarrassment.4,6 OAB-PSTQ consists of 12 questions scored on a 6-point
scale with lower scores reflecting greater satisfaction with treatment which assesses a
medication’s impact on OAB symptoms, ability to interact in social situations, and cost.4,6 PGA
is a scale that assesses patient’s symptoms, quality of life, activity limitations, and overall
emotions related to urinary incontinence.6 Each item is scored on a scale from -7 (a very great
deal worse) to +7 (a very great deal better).6
In the Nitti et al study, the King’s Health Questionnaire (KHQ), the Treatment Benefit
Scale (TBS), and the I-QOL were utilized to assess patient’s overall satisfaction with treatment
and quality of life. KHQ assesses a patient’s perception of quality of life with UI, yielding two
scores that were calculated using a series of formulas, with lower scores indicating better
HRQOL.5 Part 1 assesses the patient’s general health and incontinence impact while part 2
assesses quality of life, including physical and social limitations, relationships, emotions, sleep,
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and severity.5 TBS assesses a patient’s perception of treatment benefit by rating the progress of
their condition as either greatly improved, improved, not changed, or worsened.5
RESULTS
In the 2013 study by Chancellor et al4, 407 patients with urinary incontinence received
treatment with either 200 U onabotulinumtoxinA (n=135), 300 U onabotulinumtoxinA (n=132),
or a placebo of 0.9% saline (n=149), with 399 patients remaining at the end of the 12 week study
(98%). No differences in efficacy were established between the two doses of
onabotulinumtoxinA.4 Specifically, these patients had either multiple sclerosis or spinal cord
injury, which contributed to their urinary incontinence, and had no other pelvic or urologic
abnormalities nor prior treatment with botulinum toxin therapy. Based on the I-QOL
Questionnaire, there was a significant improvement in scoring, with a large percentage of
patients having a ≥ 11 point increase from baseline after treatment with onabotulinumtoxinA as
compared to placebo (p value < 0.001). The domain scores of avoidance/limiting behavior,
psychosocial impact, and social embarrassment also showed marked improvement after
treatment with onabotulinumtoxinA as compared to placebo (p value < 0.001, 95% CI). In
relation to the OAB-PSTQ, improvement was shown by an increase in total scoring after
treatment with onabotulinumtoxinA. At the start of the trial, 45% of all the patients classified
themselves as being somewhat or very satisfied with their current therapy, with this number
increasing to 75% in the experimental group after treatment with onabotulinumtoxinA (see Table
2). Only 45% of patients at week 6 and 30% of patients at week 12 reported this level of
satisfaction in the placebo group. The PGA revealed that patients who received the placebo
Table 2: Improvement of patient satisfaction and quality of life after treatment with
onabotulinumtoxinA
CER
EER
RBI
ABI
NNT
P-value
45%
75%
66.7%
30%
4
<0.001
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showed no change in overall symptoms, QOL, activity limitations, or overall emotions while the
experimental group with onabotulinumtoxinA reported improvements over time (p value ≤
0.001).4
Of the 557 randomized patients in the Nitti et al study5, 89% of patients who received
100 U of onabotulinumtoxinA and 88% of patients who received 10 mL saline placebo
completed the trial. Overall, the patients had a mean duration of 6.7 years of OAB, an average
use of 2.4 years worth of 2.5 anticholinergics prior to the study, and an average of 5.3 episodes
of UI. Nitti et al established that there was a statistically significant difference between
onabotulinumtoxinA and placebo.5 Per the Treatment Benefit Scale, 60.8% of the experimental
group reported a positive treatment response after onabotulinumtoxinA while only 29.2% of
placebo patients reported this response (p value < 0.001) (See Table 3). The Incontinence
Quality of Life Questionnaire and the King’s Health Questionnaire showed large, clinically
significant improvements in all domains after onabotulinumtoxinA compared to placebo
treatment (p value < 0.001, 95% CI). There was an improvement range of 19.6 to 23.9 ± SD
change from baseline in the I-QOL score for the onabotulinumtoxinA treatment group and only a
6.1-7.3 ± SD change from baseline for the placebo group. Similar improvements were noted in
Table 3: Improvement of patient satisfaction and quality of life after treatment with
onabotulinumtoxinA
CER
EER
RBI
ABI
NNT
P-value
29.2%
60.8%
108.2%
31.6%
4
<0.001
the KQH. Adverse effects were limited and most often occurred within the first 12 weeks of the
study. 15.5% of onabotulinumtoxinA patients and 5.9% of placebo contracted an uncomplicated
urinary tract infection not involving the upper urinary tract. Other complications from the
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onabotulinumtoxinA group included dysuria (12.2%), bacteriuria (5.0%), and urinary retention
(5.4%). Discontinuation rate due to adverse effects was 1.8% for the onabotulinumtoxinA group
and 1.4% for the placebo group. One death from the placebo group was reported but was
unrelated to the treatment in this study.5
In the study by Sussman et al.6, 275 patients with either multiple sclerosis or spinal cord
injury were randomized, with 92 receiving an intradetrusor placebo, 92 receiving 200 U of
onabotulinumtoxinA, and 91 receiving 300 U of onabotulinumtoxinA. Both doses of
onabotulinumtoxinA effectively reduced episodes of urinary incontinence, deeming no
differences in efficacy between the two doses of 200 U and 300 U. For both doses of the
experimental group of onabotulinumtoxinA, there was a significantly greater mean improvement
in I-QOL total score (p value < 0.001) as well as in the domain scores for avoidance/limiting
behavior, psychosocial impact, and social embarrassment (p value < 0.01) compared to the
placebo group. An inverse correlation between I-QOL total scores and UI frequency (Pearson’s
correlation coefficient at week 6 being -0.483 and -0.508 at week 12) established that decreased
frequency in urinary incontinence events were associated with improved quality of life. The
OAB-PSTQ also showed an overall improvement in total score compared to baseline for the
onabotulinumtoxinA group versus placebo (p value < 0.001). This questionnaire also reported
that a greater percentage of patients post onabotulinumtoxinA treatment reported being
“somewhat” or “very” satisfied with treatment and having “significantly met” or “exceeded”
expectations for their treatment compared to placebo (p value < 0.001) (see Table 4).
Table 4: Improvement of patient satisfaction and quality of life after treatment with
onabotulinumtoxinA
CER
EER
RBI
ABI
NNT
P-value
39.5%
77.5%
96.2%
38%
3
<0.001
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81.9% of patients receiving placebo by week 12 reported no side effects while only 62.0%63.5% of the onabotulinumtoxinA patients reported no side effects. Similar findings from the
Patient Global Assessment showed that the patients receiving onabotulinumtoxinA reported
improvement in quality of life than those who received placebo.6
DISCUSSION
The goal of this systemic review was to determine whether or not onabotulinumtoxinA
improves the quality of life in patients who have urinary incontinence, specifically overactive
bladder whose symptoms were not adequately controlled with anticholinergic treatment. Urinary
incontinence is an emotionally debilitating condition that has profound effects on a person’s
quality of life due to embarrassment, fear of UI episodes occurring in public, as well as due to
added medical complications and costs. Therefore, adequate treatment is significantly correlated
with regards to quality of life. Due to the fact that there are few pharmacological treatments
besides anticholinergics for overactive bladder, it is important to establish that
onabotulinumtoxinA causes a statistically significant improvement in quality of life. All three
randomized controlled trials were able to establish this correlation between onabotulinumtoxinA
and quality of life.
OnabotulinumtoxinA, brand name Botox in the United States, is a an FDA approved
neurotoxin that is produced by the anaerobic bacillus Clostridium botulinum.7 Its mechanism of
action is that it prevents the release of acetylcholine, producing a state of denervation.7
Specifically, onabotulinumtoxinA targets the efferent pathways of detrusor activity as well as
various targets in the bladder wall that may contribute to overactive bladder.5 Its uses are
indicated for bladder dysfunction, including detrusor overactivity and overactive bladder,
blepharospasm, cervical dystonia, chronic migraines, focal spasticity, strabismus, primary
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axillary hyperhidrosis, and for cosmetic uses to reduce facial lines.7 There is a black box
warning due to the potential of the toxin to spread beyond the area of injection within hours to
weeks after injection, leading to toxin effects, including potentially fatal swallowing and
breathing difficulties.7 A three day discontinuation of antiplatelet therapy and three days worth
of prophylactic antibiotic therapy should be given prior to and after the administration of
intradetrusor onabotulinumtoxinA to decrease the risk of urinary tract infection.7
OnabotulinumtoxinA should not be administered via intradetrusor injection to any patient with a
urinary tract infection, urinary retention, or in a patient with a post-void residual volume > 200
mL who is not utilizing self-catheterization.7 OnabotulinumtoxinA is widely available in the US
and is covered by most major insurance plans, including Medicare and Medicaid, with various
programs available to help off-set any remaining out of pocket costs. Its use has been increasing
in various specialties of medicine and as alternative treatment for many disorders.
There were various limitations to the RCTs utilized in this systematic review. Both
Chancellor et al. and Sussman et al. used the PGA which is not a validated measure for patients
with neurogenic detrusor overactivity due to spinal cord injury.4,6 Another limitation was that
the data utilized in Chancellor et al. cannot be generalized to patients with idiopathic overactive
bladder.4 Not all patients completed the OAB-PSTQ at each treatment visit by Sussman et al.
which could subsequently alter their results.6 For all studies, it was indicated that some patients
needed to initiate clean-catch intermittent catheterization (CIC) because treatment with
onabotulinumtoxinA has the potential to compromise bladder emptying. According to
Chancellor et al., this did not have a negative impact on treatment benefit with
onabotulinumtoxinA due to similar improvements in HRQOL assessments between patients who
did and did not require CIC.6
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CONCLUSION
The results of the three randomized clinical trials demonstrated that treatment with
onabotulinumtoxinA does improve the quality of life in patients with urinary incontinence not
adequately treated with anticholingergics. Along with the clinical aspects of reduced weekly
urinary incontinence episodes and improved urodynamics, patients reported increased treatment
satisfaction and as well as treatment goal attainment, ultimately improving their quality of life
and allowing them to live more fulfilled lives both emotionally and physically. An increasing
number of recent studies have found similar findings and more studies are continuing to further
explore the efficacy of onabotulinumtoxinA. Future exploration with onabotulinumtoxinA
should involve other types of urinary incontinence such as stress or overflow. Further research is
warranted to see if there is a synergistic effect between treatment with both onabotulinumtoxinA
and anticholinergics.
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